In an email to The Center for Biosimilars®, Mylan confirmed that it will launch its biosimilar pegfilgrastim at a wholesale acquisition cost (WAC) of $4175 per syringe, a price that reflects a 33% discount to the WAC of Amgen’s reference product, Neulasta.
In addition to being the first drug developer to receive FDA approval for a pegfilgrastim biosimilar, Mylan plans to launch its product, the newly approved Fulphila, at a deeper discount to its reference than any other first biosimilar launched in the US marketplace.
In an email to The Center for Biosimilars®, Mylan confirmed that it will launch its biosimilar pegfilgrastim at a wholesale acquisition cost (WAC) of $4175 per syringe, a price that reflects a 33% discount to the WAC of Amgen’s reference product, Neulasta.
Mylan’s strategy of beginning with such a substantial discount may reflect lessons learned from Celltrion and Pfizer’s launch of Inflectra. When the first biosimilar infliximab, referencing Remicade, launched at just a 15% discount to the reference’s WAC (following the example of Sandoz’s filgrastim biosimilar, Zarxio, which launched at a 15% discount to the reference Neupogen’s WAC), it struggled to gain market share.
With both the shallow discount and the reference product sponsor, Johnson & Johnson (J&J), offering incentives to continue to use the reference drug, payers saw little financial reason to undertake a change to the biosimilar. Pfizer has decried J&J’s strategies as anticompetitive in nature, and has filed suit against the Remicade maker. (J&J has countered, however, that Pfizer has not demonstrated the value of its product or a willingness to compete in the marketplace.)
With Inflectra already struggling to gain a foothold in the marketplace, Merck and Samsung Bioepis’ Renflexis, the second infliximab biosimilar to enter the US market, has seen little uptake despite its deeper launch discount of 35%.
Whether Mylan’s choice to offer such a substantial discount for its pegfilgrastim will help to overcome the hurdles of slow US biosimilar uptake remains to be seen, as does Mylan and partner Biocon’s strategy for pricing their other FDA-approved biosimilar, Ogivri, a trastuzumab product referencing Herceptin.
No launch date has been revealed for either of the Mylan—Biocon biosimilars, but the partnership made strides toward an eventual launch this month when it received the European Union’s Good Manufacturing Practice Certification for its biosimilar production plant in Bangalore, India. Manufacturing practices at the site have been called into question numerous times, most recently in May 2018, when the FDA issued a Form 483 related to 7 observations made during a preapproval inspection. In June 2018, Biocon confirmed that it had received an Establishment Inspection Report from the FDA, and that the inspection of the facility is now closed.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.